Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02206568
Other study ID # PER511
Secondary ID
Status Withdrawn
Phase Phase 1
First received
Last updated
Start date June 2014
Est. completion date September 2014

Study information

Verified date May 2015
Source AMAG Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To compare the early pharmacokinetic exposure of URAL and insulin lispro (ILisp).


Description:

To compare the total pharmacodynamic response of URAL and insulin lispro.

To compare the total pharmacokinetic exposure between URAL and insulin lispro.

To assess the safety and tolerability of URAL and insulin lispro.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date September 2014
Est. primary completion date August 2014
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Signed informed consent

2. Male subjects age 18-65 years inclusive

3. Type 1 diabetes mellitus diagnosed clinically >= 12 months

4. Treatment with multiple daily insulin injections or CSII >= 12 months

5. Current total daily insulin treatment <1.2 (I)U/kg/day

6. Current total daily bolus insulin treatment <0.7 (I)U/kg/day

7. Body mass index 18.0-30.0 kg/m2 inclusive

8. HbA1c =<9.0% by local laboratory analysis (one retest within a week is permitted with the result of the last test being conclusive)

9. C-peptide =< 0.30 nmol/L

Exclusion Criteria:

1. Known or suspected hypersensitivity to trial products or related products

2. Previous participation in this trial. .

3. Receipt of any non-marketed investigational product within 3 months

4. Clinically significant abnormal haematology, biochemistry, liver enzymes, or coagulation screening tests

5. Suffer from or history of a life threatening disease or any clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, haematological, dermatological, venereal , neurological, psychiatric diseases or other major disorders

6. History of deep leg vein thrombosis or a frequent appearance of deep leg vein thrombosis in 1st degree relatives

7. Cardiac problems defined as decompensated heart failure (New York Heart Association class III and IV) at any time and/or angina pectoris within the last 12 months and/or acute myocardial infarction at any time.

8. Supine blood pressure at screening outside the range of 90-140 mmHg for systolic or 50-90 mmHg for diastolic . Pulse outside 50 to 90 bpm.

9. Clinically significant abnormal ECG at screening.

10. Proliferative retinopathy or maculopathy and/or severe neuropathy, in particular autonomic neuropathy.

11. Any disease or condition that, in the opinion of the Investigator, would represent an unacceptable risk for the subject's safety.

12. Subject positive for HBs-Ag, HCV-Ab

13. Positive result to the screening test for HIV-1 antibodies, HIV-2 antibodies, or HIV-1 antigen according to locally used diagnostic testing.

14. History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.

15. Subject who has donated blood or plasma in the past month or more than 500 mL within 3 months.

16. Surgery or trauma with significant blood loss (more than 500 mL) within 3 months.

17. Current treatment with systemic (oral, IV, or inhaled) corticosteroids, monoamine oxidase inhibitors, NSAID, prostaglandin blockers, systemic non-selective beta-blockers, growth hormone (last 3 months), non-routine vitamins or herbal products (last 2 weeks). Thyroid hormones are not allowed unless the use of these has been stable during the last 3 months. Routine vitamins are permitted up to 48 hours prior to dosing.

18. Significant history of alcoholism and/or drug/chemical abuse as per Investigator's judgement or a positive result in the urine drug/alcohol breath test screen at the screening visit.

19. Heavy smoker

20. Not able or willing to refrain from smoking and use of nicotine.

21. Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemia event during the last 12 months) or hypoglycaemic unawareness.

22. Subject with mental incapacity or language barriers precluding adequate understanding.

23. Potentially non-compliant or uncooperative during the trial.

24. Any condition that would interfere with trial participation or evaluation of results.

25. No relevant lipodystrophy within the area of drug administration and Doppler sonography.

Study Design


Intervention

Drug:
URAL


Locations

Country Name City State
Germany Profil Institut fur Stoffwechselforschung GmbH Neuss

Sponsors (2)

Lead Sponsor Collaborator
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. Profil Institut für Stoffwechselforschung GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pharmacokinetics of URAL Area under the serum insulin lispro concentration-time curve from 0-30 minutes after administration 1 day
Secondary Onset of appearance of serum insulin lispro Measurement of time to reach insulin lispro concentration >30 pmol/L in the serum 1 day
Secondary Number of subjects with adverse events Assessment of safety and tolerability of URAL 1 day
See also
  Status Clinical Trial Phase
Completed NCT04476472 - Omnipod Horizon™ Automated Glucose Control System Preschool Cohort N/A
Completed NCT03635437 - Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes Phase 1/Phase 2
Completed NCT04909580 - Decision Coaching for Youth and Parents Considering Insulin Delivery Methods for Type 1 Diabetes N/A
Active, not recruiting NCT00679042 - Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol Phase 3
Completed NCT03293082 - Preschool CGM Use and Glucose Variability in Type 1 Diabetes N/A
Completed NCT04016662 - Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D) Phase 4
Completed NCT02527265 - Afrezza Safety and Pharmacokinetics Study in Pediatric Patients Phase 2
Completed NCT03738865 - G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes Phase 3
Completed NCT03240432 - Wireless Innovation for Seniors With Diabetes Mellitus N/A
Completed NCT03168867 - Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms) N/A
Completed NCT03674281 - The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System N/A
Completed NCT03669770 - Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes
Recruiting NCT03682640 - Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes Phase 2
Recruiting NCT04096794 - Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
Completed NCT02882737 - The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus N/A
Recruiting NCT02745808 - Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Withdrawn NCT02579148 - Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Completed NCT02562313 - A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog® Phase 1
Completed NCT02596204 - Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring N/A
Withdrawn NCT02518022 - How to be Safe With Alcoholic Drinks in Diabetes N/A